Predict your next investment

Corporation
curraxpharma.com

See what CB Insights has to offer

About Currax Pharmaceuticals

Currax Pharmaceuticals is a specialty pharmaceutical business focused on acquiring and commercializing prescription drugs within the US market. Currax distributes a range of both branded and generic pharmaceutical products.

Currax Pharmaceuticals Headquarter Location

10 North Park Place Suite 201

Morristown, New Jersey, 07960,

United States

800-793-2145

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Currax Pharmaceuticals News

Global Anti-Obesity Drugs Market Report 2021 Featuring Alizyme, Arena Pharmaceuticals, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Currax Pharmaceuticals

Aug 23, 2021

The Global Anti-Obesity Drugs Market is estimated to be USD 3.28 Bn in 2021 and is expected to reach USD 4.64 Bn by 2026, growing at a CAGR of 7.19%. Increased consumption of processed and unhealthy foods, lack of physical activity, lack of knowledge about the risk associated with obesity, and rising disposable money are some factors driving the demand for anti-obesity drugs. Furthermost, the rising worry about being overweight or obese is exposing people to a greater risk of developing a variety of chronic illnesses, such as cardiovascular disease, cancer, and diabetes, etc., all of which have high treatment costs, so the public has become more conscious of obesity, which is prompting consumers to turn to anti-obesity medications. In addition, the increasing healthcare spending, favorable reimbursement policies, substantial research and development efforts in the sector, and increased government and non-government organizations' participation in raising awareness and funding research are expected to create more opportunities for the growth of this market. However, medication side effects, restricted availability of combination therapy, and growing acceptance of other options such as gyms, exercise spas, and other alternatives are likely to restrain and create a challenge for the global anti-obesity drugs market. Some of the companies covered in this report are Alizyme, Arena Pharmaceuticals Inc, Bayer AG, Boehringer Ingelheim GmbH, Bristol-Myers Squibb, Currax Pharmaceuticals LLC, etc. Market Segmentation The Global Anti-Obesity Drugs Market is segmented further based on Drug Type, Drug Class, Medication, Distribution Channel, and Geography. By Drug Type, the market is classified as prescription drugs and OTC drugs. Amongst the two, the prescription drugs segment is estimated to hold the highest market share during the forecast period. By Drug Class, the market is classified as peripherally acting drugs and centrally acting drugs. Amongst the two, the peripherally acting drugs segment is estimated to hold the highest market share during the forecast period. By Medication, the market is classified as Monotherapies, Polytherapies, and others, others. Amongst all, the monotherapies segment is estimated to hold the highest market share during the forecast period. By Distribution Channel, the market is classified as hospital pharmacy, retail pharmacy, and online pharmacy. All the hospital pharmacy segment is estimated to hold the highest market share during the forecast period. Recent Developments FDA accepts Eisai's supplemental new drug application (SNDA) to update the labeling for anti-obesity agent Belviq. - 25th February 2019. CurraxT Pharmaceuticals LLC Announces the Acquisition of Nalpropion Pharmaceuticals, Inc. - 27th September 2019. Currax Launches Why Weight: Communicate Initiative to Encourage Conversations about Weight Loss- 25th June 2021 Key Topics Covered:

Currax Pharmaceuticals Acquisitions

1 Acquisition

Currax Pharmaceuticals acquired 1 company. Their latest acquisition was Nalpropion Pharmaceuticals on September 27, 2019.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

9/27/2019

Acquired

2

Date

9/27/2019

Investment Stage

Companies

Valuation

Total Funding

Note

Acquired

Sources

2

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.